Neuropathy News and Research

RSS

Araim Pharmaceuticals forms new strategic collaboration with Vault Bioventures to market novel peptides

Araim Pharmaceuticals has formed a long-term strategic partnership with Vault Bioventures to facilitate the advancement to market of its novel peptide library which targets devastating injuries and chronic diseases underserved by current therapies.

4 Jan 2016

Nuvo Research announces topline results from WF10 Phase 2 trial for treatment of allergic rhinitis

Nuvo Research Inc., a life sciences company with growing revenues and a diverse portfolio of topical products, today announced the results of its investigational Phase 2 clinical trial of WF10 (Trial) for the treatment of allergic rhinitis.

21 Dec 2015

$Role for carfilzomib in relapsed, refractory multiple myeloma treatment$

Role for carfilzomib in relapsed, refractory multiple myeloma treatment

Carfilzomib significantly improves outcomes in previously treated patients with relapsed or refractory multiple myeloma, shows a head-to-head comparison with bortezomib.

11 Dec 2015

Takeda presents Phase 3 TOURMALINE-MM1 data for multiple myeloma at ASH 2015

Takeda Pharmaceutical Company Limited today announced results from the TOURMALINE-MM1 trial presented at the 57th Annual Meeting and Exposition of the American Society of Hematology (ASH), showing that treatment with NINLARO (ixazomib) capsules is effective in extending progression free survival (PFS) with a manageable tolerability profile in patients with relapsed and/or refractory multiple myeloma.

8 Dec 2015

FDA grants approval for Empliciti (elotuzumab) to treat patients with multiple myeloma

Today the U.S. Food and Drug Administration granted approval for Empliciti (elotuzumab) in combination with two other therapies to treat people with multiple myeloma who have received one to three prior medications.

30 Nov 2015

Ninlaro (ixazomib) approved to treat people with multiple myeloma

Today the U.S. Food and Drug Administration granted approval for Ninlaro (ixazomib) in combination with two other therapies to treat people with multiple myeloma who have received at least one prior therapy.

21 Nov 2015

Global tissue engineered medical devices market expected to cross US$ 26 billion by 2020

According to recently published Pharmaion report, "Global Tissue Engineered Medical Devices Market Forecast & Opportunities, 2020", global tissue engineered medical devices market is anticipated to cross US$ 26 billion by 2020.

19 Nov 2015

MedUni Vienna researchers discover genetic cause of a rare disease

Researchers at MedUni Vienna have discovered the genetic cause of a rare disease characterized by life-threatening "liver crises" in early childhood and subsequent manifestation of neurological symptoms, such as neuropathy and ataxia (a movement disorder), when they reach school age.

15 Nov 2015

Alnylam presents positive ongoing phase 2 open-label extension data for Patisiran and Revusiran

Alnylam Pharmaceuticals, Inc. has announced new results from its ongoing Phase 2 open-label extension (OLE) studies with patisiran and revusiran, investigational RNAi therapeutics targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR amyloidosis).

3 Nov 2015

United Cannabis files utility and PCT patent applications related to unique specifications of cannabinoids

United Cannabis Corporation today announced that it moved its provisional patent application to the next phase by filing a utility patent application related to the unique combinations of pharmaceutically active cannabinoids used to treat disorders of the nervous system, immune system and cancer with the U.S. Patent and Trademark Office.

3 Nov 2015

University of Arkansas biomedical engineer awarded NIH grant to study chronic wound biomarkers

The National Institutes of Health awarded a University of Arkansas biomedical engineer a new $744,992 grant to improve imaging and early detection of chronic wounds and guide treatments.

22 Oct 2015

New study from TSRI and Salk points to cause of debilitating nerve disease

Scientists at The Scripps Research Institute (TSRI) and the Salk Institute for Biological Studies have discovered how a mutant protein triggers nerve damage in a subtype of Charcot-Marie-Tooth (CMT) diseases, a group of currently untreatable conditions that cause loss of function in a person’s hands and feet.

22 Oct 2015

BDSI announces FDA approval of BUNAVAIL sNDA for manufacturing specification change

BioDelivery Sciences International, Inc. announced that the U.S. Food and Drug Administration has approved the company's Supplemental New Drug Application (sNDA) for a manufacturing specification change for BUNAVAIL (buprenorphine and naloxone) buccal film (CIII).

15 Oct 2015

NIH-funded researchers test new gene therapy to improve visual function in mice

Researchers funded by the National Institutes of Health have developed a novel mouse model for the vision disorder Leber hereditary optic neuropathy (LHON), and found that they can use gene therapy to improve visual function in the mice. LHON is one of many diseases tied to gene mutations that damage the tiny energy factories that power our cells, called mitochondria.

6 Oct 2015

Bretuximab vedotin safe, effective for older Hodgkin lymphoma patients unfit for chemotherapy

A study, published online in Blood, the Journal of the American Society of Hematology, reports that bretuximab vedotin is an effective and safe first course of treatment for older Hodgkin lymphoma patients unfit for chemotherapy.

22 Sep 2015

Ups and downs of incorporating new treatment to reduce oxaliplatin-induced neuropathy

In this age of the 24-hour news cycle, instant access to all information everywhere, PubMed, LinkedIn, Facebook, Twitter and hundreds of other ways to glean and share knowledge beyond the traditional stack of printed journals delivered to their door, physicians continue to struggle to arm themselves with the most effective therapies.

21 Sep 2015

Study shows reduced heart rate variability may be contributing risk factor for PTSD

A prospective longitudinal study of U.S. Marines suggests that reduced heart rate variability - the changing time interval between heartbeats - may be a contributing risk factor for post-traumatic stress disorder (PTSD).

11 Sep 2015

Innovative technologies offer hope to people living with chronic pain

More than 100 million people in this country have pain that won't go away. Many of these chronic pain sufferers fail to get relief from pills, shots and even surgery, while others temporarily trade the pain for side effects such as drowsiness or digestive problems.

11 Sep 2015

Researchers discover new strategy for attacking cancer cells

University of Virginia School of Medicine researchers have discovered a new strategy for attacking cancer cells that could fundamentally alter the way doctors treat and prevent the deadly disease.

11 Sep 2015

UVA researchers identify new strategy for attacking cancer cells

University of Virginia School of Medicine researchers have discovered a new strategy for attacking cancer cells that could fundamentally alter the way doctors treat and prevent the deadly disease. By more selectively targeting cancer cells, this method offers a strategy to reduce the length of and physical toll associated with current treatments.

10 Sep 2015

Neuropathy News and Research

Araim Pharmaceuticals forms new strategic collaboration with Vault Bioventures to market novel peptides

Nuvo Research announces topline results from WF10 Phase 2 trial for treatment of allergic rhinitis

Role for carfilzomib in relapsed, refractory multiple myeloma treatment

Takeda presents Phase 3 TOURMALINE-MM1 data for multiple myeloma at ASH 2015

FDA grants approval for Empliciti (elotuzumab) to treat patients with multiple myeloma

Ninlaro (ixazomib) approved to treat people with multiple myeloma

Global tissue engineered medical devices market expected to cross US$ 26 billion by 2020

MedUni Vienna researchers discover genetic cause of a rare disease

Alnylam presents positive ongoing phase 2 open-label extension data for Patisiran and Revusiran

United Cannabis files utility and PCT patent applications related to unique specifications of cannabinoids

University of Arkansas biomedical engineer awarded NIH grant to study chronic wound biomarkers

New study from TSRI and Salk points to cause of debilitating nerve disease

BDSI announces FDA approval of BUNAVAIL sNDA for manufacturing specification change

NIH-funded researchers test new gene therapy to improve visual function in mice

Bretuximab vedotin safe, effective for older Hodgkin lymphoma patients unfit for chemotherapy

Ups and downs of incorporating new treatment to reduce oxaliplatin-induced neuropathy

Study shows reduced heart rate variability may be contributing risk factor for PTSD

Innovative technologies offer hope to people living with chronic pain

Researchers discover new strategy for attacking cancer cells

UVA researchers identify new strategy for attacking cancer cells

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News